China Biologic draws investor flak over rejected takeover bid

China Biologic draws investor flak over rejected takeover bid

An investor in China Biologic Products Holdings Inc. has criticized the biopharmaceutical company for rejecting a $3.9 billion takeover bid, saying it should consider all options to maximize shareholder value and unwind a private placement that created a controlling group of insiders.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter